euro-cardiology-2017-posters-accepted-abstracts

Page 101

Notes:

conferenceseries

.com

Volume 8, Issue 9 (Suppl)

J Clin Exp Cardiolog, an open access journal

ISSN: 2155-9880

Euro Cardiology 2017

October 16-18, 2017

October 16-18, 2017 | Budapest, Hungary

European

Cardiology

Conference

J Clin Exp Cardiolog 2017, 8:9(Suppl)

DOI: 10.4172/2155-9880-C1-078

Hypertension treatment in patients with metabolic syndrome and type 2 diabetes analysis of the

therapy and the therapeutic inertia in outpatient´s study

Štefan Farský, Andrea Strišková

and

Marián Borčin

Slovak League against Hypertension, Slovakia

he subject of this thesis is to study the effectivity of hypertension treatment as for as drug choice, decrease of sBP and

dBP associated with certain drug, drug combination and therapeutic inertia in patients with metabolic syndrome and/

or diabetes mellitus. We have analyzed the database of 1595 consecutive patients visiting our department of cardiology and

internal medicine clinic in years 2005-2014. The study included 13990 visit records, average number of visits per patient

was 8,5+-7,0. Final number of patients who fulfilled inclusion criteria for interpenetration of both diagnoses was 570. By

hypertension monotherapy were treated 15% patients, by 2-4 drug combination therapy 70% and by 5-6 drug combination

15% patients. The most frequent used drugs were perindopril, nitrendipine, amlodipine, telmisartan, hydrochlorothiazide,

rilmenidine and nebivolol (used >100 patients). The most significant decrease of sBP was associated with treatment by

nitredipine, hydrochlorotiazide, telmi and urapidil (>19mmHg).The most significant decrease of dBP was associated with

treatment by nitredipine, hydrochlorotiazide, telmisartan and verapamil (>10mmHg). The most significant decrease of both

sBP and dBP was associated with 3 drug combination treatment of telmisartan-hydrochlorotiazide-spironolacton (41 resp.

16mmHg), telmisartan-hydrochlorotiazide-nitredipine (34 resp.15 mmHg) and telmisartan-hydrochlorotiazide-urapidil (34

resp. 15 mmHg). At the last visit 281 from 413 patients at the first visit have had sBP >140 mmHg (68%) i.e. sBP control was

32%. At the last visit 76 patients from 217 at the first visit have had dBP >90 mmHg (35%) i.e. dBP control was 65%. The score

of therapeutic inertia was counted at first 200 consecutive patients with the average value 57,30+-147,20.